TransThera Biosci 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tinengotinib (TT-00420) / TransThera Biosci
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Completed
2
55
US
TT-00420
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
02/24
02/24
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Recruiting
2
50
RoW
TT-00420 (tinengotinib)
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma Metastatic
06/25
10/25
NCT07052253: A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

Not yet recruiting
2
100
RoW
TT-00420 (tinengotinib), AK104, AK112
Akeso, TransThera Sciences (Nanjing), Inc.
Hepatocellular Carcinoma (HCC)
05/27
12/27
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Completed
1/2
84
RoW
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer
08/24
08/24
NCT04742959: Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Completed
1/2
203
US
TT-00420, Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
02/24
02/24
IUNU-PC-121, NCT06221774: Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors

Not yet recruiting
1/2
42
RoW
TT-00420 + Toripalimab
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Clear Cell Renal Carcinoma, Urothelial Carcinoma, Metastatic Castration-resistant Prostate Cancer
08/25
11/25
NCT06457919: A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Recruiting
1/2
50
US
Tinengotinib, TT-00420, abiraterone acetate with prednisone, Enzalutamide
Memorial Sloan Kettering Cancer Center, TransThera Sciences
Prostate Cancer
06/27
06/27
NCT03654547: Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

Active, not recruiting
1
48
US, RoW
TT-00420
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumors, Triple Negative Breast Cancer
01/23
02/24
NCT06370013: Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors

Available
N/A
US
Tinengotinib, TT-00420
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumors, Cholangiocarcinoma
 
 
TT-00920 / TransThera Biosci
NCT04364789: Phase I, First-In-Human Study of TT-00920 in Healthy Subjects

Completed
1
42
US
TT-00920, Placebos
TransThera Sciences (Nanjing), Inc.
Healthy
06/21
03/22
NCT05043792: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects

Completed
1
20
US
TT-00920, TT-00920 Placebo
TransThera Sciences (Nanjing), Inc.
Healthy
11/21
11/21
NCT05355129: A Phase 1 Study of TT-00920 in Healthy Subjects

Completed
1
30
RoW
TT-00920, TT-00920 Placebo
TransThera Sciences (Nanjing), Inc.
Healthy
06/22
06/22
TT-00434 / TransThera Biosci
NCT04830501: Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors

Completed
1
11
RoW
TT-00434
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumors
10/23
10/23
TT-01488 / TransThera Biosci
NCT05275504: Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting
1
37
US
TT-01488
TransThera Sciences (Nanjing), Inc.
B-Cell Malignancies
09/22
04/23
TT01488CN02, NCT05683717: A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting
1
37
RoW
TT-01488 Tablets
TransThera Sciences (Nanjing), Inc.
B-Cell Malignancies
10/26
10/28
TT-00973 / TransThera Biosci
NCT05673538: TT-00973-MS Tablets in Patients With Advanced Solid Tumors

Not yet recruiting
1
40
RoW
TT-00973-MS tablets treatment
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor
12/24
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tinengotinib (TT-00420) / TransThera Biosci
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Completed
2
55
US
TT-00420
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
02/24
02/24
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Recruiting
2
50
RoW
TT-00420 (tinengotinib)
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma Metastatic
06/25
10/25
NCT07052253: A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

Not yet recruiting
2
100
RoW
TT-00420 (tinengotinib), AK104, AK112
Akeso, TransThera Sciences (Nanjing), Inc.
Hepatocellular Carcinoma (HCC)
05/27
12/27
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Completed
1/2
84
RoW
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer
08/24
08/24
NCT04742959: Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Completed
1/2
203
US
TT-00420, Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
02/24
02/24
IUNU-PC-121, NCT06221774: Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors

Not yet recruiting
1/2
42
RoW
TT-00420 + Toripalimab
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Clear Cell Renal Carcinoma, Urothelial Carcinoma, Metastatic Castration-resistant Prostate Cancer
08/25
11/25
NCT06457919: A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Recruiting
1/2
50
US
Tinengotinib, TT-00420, abiraterone acetate with prednisone, Enzalutamide
Memorial Sloan Kettering Cancer Center, TransThera Sciences
Prostate Cancer
06/27
06/27
NCT03654547: Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

Active, not recruiting
1
48
US, RoW
TT-00420
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumors, Triple Negative Breast Cancer
01/23
02/24
NCT06370013: Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors

Available
N/A
US
Tinengotinib, TT-00420
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumors, Cholangiocarcinoma
 
 
TT-00920 / TransThera Biosci
NCT04364789: Phase I, First-In-Human Study of TT-00920 in Healthy Subjects

Completed
1
42
US
TT-00920, Placebos
TransThera Sciences (Nanjing), Inc.
Healthy
06/21
03/22
NCT05043792: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects

Completed
1
20
US
TT-00920, TT-00920 Placebo
TransThera Sciences (Nanjing), Inc.
Healthy
11/21
11/21
NCT05355129: A Phase 1 Study of TT-00920 in Healthy Subjects

Completed
1
30
RoW
TT-00920, TT-00920 Placebo
TransThera Sciences (Nanjing), Inc.
Healthy
06/22
06/22
TT-00434 / TransThera Biosci
NCT04830501: Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors

Completed
1
11
RoW
TT-00434
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumors
10/23
10/23
TT-01488 / TransThera Biosci
NCT05275504: Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting
1
37
US
TT-01488
TransThera Sciences (Nanjing), Inc.
B-Cell Malignancies
09/22
04/23
TT01488CN02, NCT05683717: A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting
1
37
RoW
TT-01488 Tablets
TransThera Sciences (Nanjing), Inc.
B-Cell Malignancies
10/26
10/28
TT-00973 / TransThera Biosci
NCT05673538: TT-00973-MS Tablets in Patients With Advanced Solid Tumors

Not yet recruiting
1
40
RoW
TT-00973-MS tablets treatment
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor
12/24
12/25

Download Options